Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed By Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer (ETNBC) in France

Category Primary study
JournalValue in Health
Year 2023
This article has no abstract
Epistemonikos ID: 89618428d60e2dd483a925e53f16871622173ea1
First added on: Feb 17, 2025